Trade Report: Today: Eagle Asset Management Inc. Buys Shares of 124,013 Illumina Inc. (ILMN)

Today: Eagle Asset Management Inc. Buys Shares of 124,013 Illumina Inc. (ILMN)

Eagle Asset Management Inc. purchased a new position in shares of Illumina Inc. (NASDAQ:ILMN) during the third quarter, Holdings Channel reports. The firm purchased 124,013 shares of the life sciences company’s stock, valued at approximately $22,528,000.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Nuveen Asset Management LLC raised its position in Illumina by 22.6% in the first quarter. Nuveen Asset Management LLC now owns 9,655 shares of the life sciences company’s stock worth $1,565,000 after buying an additional 1,781 shares in the last quarter. Euclid Advisors LLC raised its position in Illumina by 613.2% in the first quarter. Euclid Advisors LLC now owns 32,451 shares of the life sciences company’s stock worth $5,261,000 after buying an additional 27,901 shares in the last quarter. NEXT Financial Group Inc raised its position in Illumina by 31.0% in the second quarter. NEXT Financial Group Inc now owns 3,006 shares of the life sciences company’s stock worth $421,000 after buying an additional 711 shares in the last quarter. DNB Asset Management AS raised its position in Illumina by 2.7% in the second quarter. DNB Asset Management AS now owns 11,489 shares of the life sciences company’s stock worth $1,613,000 after buying an additional 300 shares in the last quarter. Finally, Exxonmobil Investment Management Inc. TX raised its position in Illumina by 6.5% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 38,103 shares of the life sciences company’s stock worth $5,349,000 after buying an additional 2,312 shares in the last quarter. 92.98% of the stock is currently owned by institutional investors.

Shares of Illumina Inc. (NASDAQ:ILMN) traded up 0.48% during mid-day trading on Monday, hitting $135.84. The stock had a trading volume of 644,508 shares. The stock’s 50-day moving average is $140.46 and its 200-day moving average is $152.80. Illumina Inc. has a 1-year low of $127.10 and a 1-year high of $196.47. The firm has a market capitalization of $19.95 billion, a PE ratio of 45.58 and a beta of 1.24.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The firm had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. During the same period last year, the firm posted $0.80 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. Equities analysts expect that Illumina Inc. will post $3.32 earnings per share for the current year.

ILMN has been the topic of a number of recent analyst reports. Vetr raised shares of Illumina from a “strong sell” rating to a “sell” rating and set a $155.68 price target on the stock in a research report on Monday, August 1st. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Argus boosted their target price on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. CL King lowered shares of Illumina from a “buy” rating to a “neutral” rating in a research report on Monday, August 22nd. Finally, Citigroup Inc. boosted their target price on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company. Illumina currently has an average rating of “Hold” and a consensus price target of $152.88.

In related news, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $136.34, for a total transaction of $81,804.00. Following the completion of the transaction, the director now directly owns 17,065 shares in the company, valued at approximately $2,326,642.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Marc Stapley sold 1,270 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $172.87, for a total value of $219,544.90. Following the transaction, the executive vice president now owns 33,916 shares of the company’s stock, valued at $5,863,058.92. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Related posts

Leave a Comment